Want to see JP:2929 full AI Analyst Report?
Pharma Foods International Co., Ltd. (2929) AI Stock Analysis
Pharma Foods International Co., Ltd.
(TSE/TYO:2929)
The overall score is constrained by poor financial fundamentals, specifically negative operating cash flow and declining revenue, which signal high risk. This is partially offset by strong bullish momentum in the stock price and an attractive valuation with a low P/E ratio and solid dividend yield. The company's high gross margins and debt reduction are positive, but are overshadowed by the critical cash flow weakness.
Pharma Foods International Co., Ltd. (2929) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 18.44B
- Dividend Yield
- 3.46%
- Average Volume (3M)
- 223.46K
- Price to Earnings (P/E)
- 9.3
- Beta (1Y)
- 0.79
- Revenue Growth
- -3.12%
- EPS Growth
- 406.78%
- Country
- Japan
- Employees
- 613
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Pharma Foods International Co., Ltd. Business Overview & Revenue Model
Company Description
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a spe...
How the Company Makes Money
Pharma Foods International primarily makes money by selling branded health-related consumer products, especially dietary supplements and other functional food/wellness items. Revenue is generated when customers purchase these products through the com...
Pharma Foods International Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. Revenue is declining, net margins are razor-thin and volatile, and operating cash flow has been negative for two consecutive years, indicating poor earnings quality. The only bright spot is high gross margins and reduced leverage, but the inability to convert profits to cash is a critical risk.
Income Statement
45NeutralBalance Sheet
55NeutralCash Flow
30Negative| Breakdown | TTM | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.22B | 63.22B | 65.26B | 62.15B | 68.57B | 60.19B |
| Gross Profit | 50.66B | 50.66B | 52.53B | 48.65B | 55.21B | 48.06B |
| EBITDA | 3.37B | 3.37B | 3.15B | 6.02B | 4.16B | 1.60B |
| Net Income | 1.99B | 1.99B | 368.00M | 3.21B | 3.08B | -374.00M |
Balance Sheet | ||||||
| Total Assets | 35.12B | 35.12B | 32.78B | 36.57B | 36.23B | 31.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.79B | 7.79B | 9.16B | 15.67B | 16.31B | 8.85B |
| Total Debt | 17.17B | 17.17B | 12.66B | 16.90B | 20.12B | 16.89B |
| Total Liabilities | 21.95B | 21.95B | 21.23B | 24.99B | 26.60B | 24.08B |
| Stockholders Equity | 13.17B | 13.17B | 11.55B | 11.59B | 9.63B | 7.07B |
Cash Flow | ||||||
| Free Cash Flow | -5.19B | -5.19B | -1.98B | 4.54B | 5.74B | -6.53B |
| Operating Cash Flow | -1.18B | -1.18B | -1.09B | 5.49B | 6.13B | -6.07B |
| Investing Cash Flow | -4.00B | -4.00B | -950.00M | -1.39B | -1.01B | -2.54B |
| Financing Cash Flow | 3.81B | 3.81B | -4.47B | -4.84B | 2.34B | 7.68B |
Pharma Foods International Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Negative. The current price of 618.00 is below the 20-day moving average (MA) of 675.05, below the 50-day MA of 661.12, and below the 200-day MA of 628.30, indicating a neutral trend. The MACD of -6.92 indicates Positive momentum. The RSI at 35.29 is Neutral, neither overbought nor oversold. The STOCH value of 5.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2929.
Pharma Foods International Co., Ltd. Peers Comparison
Overall Rating
JP:452481.5Outperform
JP:454065Neutral- JP:292959Neutral
JP:453946.5Neutral
JP:451245Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4524 | 82Outperform | JPY 8.95B | 11.40 | ― | 2.96% | 0.98% | 69.36% |
| JP:4540 | 65Neutral | JPY 292.34B | 9.43 | 9.68% | 4.14% | 10.38% | 19.96% |
| JP:2929 | 59Neutral | JPY 18.40B | 9.29 | ― | 3.46% | -3.12% | 406.78% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
| JP:4512 | 45Neutral | JPY 10.52B | 30.73 | ― | 1.16% | 25.89% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2929 | Pharma Foods International Co., Ltd. | 618.00 | -164.04 | -20.98% | |
| JP:4540 | Tsumura & Co | 3826.00 | 391.81 | 11.41% | |
| JP:4512 | Wakamoto Pharmaceutical Co., Ltd. | 300.00 | 12.42 | 4.32% | |
| JP:4524 | Morishita Jintan Co., Ltd. | 2190.00 | 133.01 | 6.47% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1494.00 | 9.29 | 0.63% |
Pharma Foods International Co., Ltd. Corporate Events
Pharma Foods Profit Soars Despite Lower Sales, Eyes Further Gains in 2027
Pharma Foods International reported a 3.1% decline in net sales to ¥63.2 billion for the year ended July 31, 2026, but operating profit rose 11.2% to ¥2.6 billion and profit attributable to owners of parent surged to ¥2.0 billion, lift...
Pharma Foods Books Impairment Loss on Onkyo Investment with Limited Consolidated Impact
Pharma Foods International Co., Ltd. has booked a special loss in its non-consolidated results for the fiscal year ended July 2026, after recognizing an impairment on its equity-method investment in Onkyo Corporation. The company concluded that recov...
Pharma Foods Raises Profit Outlook Despite Lower Sales in FY2026
Pharma Foods International has revised its full-year forecasts for the fiscal year ended July 2026, projecting lower net sales but higher profits than previously expected. Net sales are now seen at JPY 63.2 billion versus a prior JPY 67 billion, whil...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 12, 2026